Investing.com - Guggenheim周四将Nautilus Biotechnology(NASDAQ:NAUT)的目标价从2.50美元上调至4.00美元,同时维持买入评级。新目标价较当前股价2.42美元有65%的上涨空间,而该股在过去六个月已经实现了245%的惊人回报。 该公司表示,Nautilus年末的运营亏损好于华尔街预期,使公司在2027年推出产品前的高投资年度到来之前,在现 ...
Puma Biotechnology (NASDAQ:PBYI) reported fourth-quarter 2025 total revenue of $75.5 million, driven by NERLYNX product ...
这家处于临床阶段的生物制药公司将发行1764.7058万股普通股,预计在扣除承销折价和佣金前将获得1.5亿美元的总收益。Vir Biotechnology还授予承销商30天的选择权,可以按公开发行价格额外购买最多264.7058万股。
在今日的股市交易中，Vir Biotechnology (VIR.US) 的股价表现引人注目，最高涨幅超过38%，触及10.29美元，创下逾一年以来的新高。这一涨幅的主要驱动力来自于公司发布的第四季度财报，其营收为6407万美元，同比大幅增长417%，超出市场预期的4416万美元。此外，每股亏损改善至0.31美元，相较于去年同期的0.76美元显著好转，显示出公司在财务上的积极变化。
引言生物分子的定向进化 (Directed Evolution) 长期以来被视为一种模拟自然选择的艺术。无论是蛋白质还是核酸，通过迭代筛选获得功能分子的过程，往往意味着数周甚至数月的高强度实验。尤其是对于 RNA 适配体 (RNA Aptamers) ...
The biotechnology market is entering a new growth phase, driven by the convergence of genomic science, artificial intelligence, and precision medicine, as global R&D investment approaches $360 billion ...
Experts discuss biotechnology's role in advancing personalized medicine at a VIT webinar, highlighting career opportunities ...
Sana Biotechnology Inc. (NASDAQ:SANA) is one of the most promising penny stocks under $5 to buy. On February 17, Sana ...
The Well News on MSNOpinion
Biotechnology is the new national security frontier - and America is falling behind
The United States has long led the global biomedical research and pharmaceutical development industry - but that leadership ...
The consensus estimate for Q4 2025 revenue is $23.18 million, and the earnings are expected to come in at -$0.41 per share. The full year 2025's revenue is expected to be $19.22 million, and the ...
The Department of Biotechnology, under the Ministry of Science and Technology has released notification for the Scientist 'C' posts.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果